Form 4: Rallybio Director Acquires Options in Lieu of Retainer Fees
SEC Form 4 Filing
Rallybio director Martin Mackay acquired options for 92,857 shares of common stock in lieu of $65,000 in retainer fees.
Summary
- Martin Mackay, a director at Rallybio Corp, acquired options to purchase 92,857 shares of common stock.
- The options were granted on January 2, 2025, with an exercise price of $0.95 per share.
- These options were issued in lieu of $65,000 in retainer fees under the company's 2021 Equity Incentive Plan.
- The options vest in 12 equal monthly installments throughout 2025.
- The options expire on January 2, 2035.
Sentiment
Score: 7
Explanation: The document reflects a standard compensation practice, which is generally viewed positively as it aligns director interests with shareholders. There are no negative implications.
Positives
- The use of equity in lieu of cash for director compensation can be seen as a positive sign of alignment between management and shareholders.
- The vesting schedule encourages long-term commitment from the director.
Risks
- The exercise of these options could potentially dilute existing shareholders if the options are exercised.
Industry Context
The use of stock options as part of director compensation is a common practice in the biotechnology industry, aligning director interests with company performance.
Comparison to Industry Standards
- Granting options in lieu of cash compensation is a common practice among biotech companies, especially those in the early stages of development, such as Rallybio.
- This approach is similar to companies like Xencor and BioMarin, which also use equity-based compensation to attract and retain talent.
- The vesting schedule of 12 months is also standard practice in the industry.
Stakeholder Impact
- Shareholders may view this as a positive sign of alignment between management and company performance.
- Employees may see this as a standard practice for director compensation.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Date of option grant and commencement of vesting. |
| 01/06/2025 | Date of filing of the Form 4. |
| 01/02/2035 | Expiration date of the options. |
Keywords
options, equity, director, Rallybio, RLYB, compensation, insider trading, form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.